INICIO

Continuation of the Revista Mexicana de Cardiología

    
  • Home
  • Instructions for authors
  • Publish
  • Directory
  • Publications
    • Current issue                  
    • All issues
  • Contact





2022, Supplement 3

Cardiovasc Metab Sci 2022; 33 (S3)

Impact of alternative therapies in the treatment of resistant systemic arterial hypertension

Díaz-y-Díaz, Enrique; Parcero-Valdés, Juan José

ABSTRACT

Resistant arterial hypertension has been defined as a condition where a patient is being treated with an antihypertensive regimen with ≥ 4 drugs or ≥ 3 drugs that include a diuretic and still has blood pressure figures ≥ 140/90 mmHg. Given that the prevalence of resistant arterial hypertension is high, clinicians should be aware of its potential risk of not handling this condition. This review aims to discuss contributors and clinical recommendations to help clinicians better understand and treat resistant arterial hypertension within all care settings. We also demonstrate data from randomized placebo-controlled trials and conclude that renal denervation significantly reduces ambulatory and office blood pressure. Moreover, it was similar between patients on and off background antihypertensive medications. Furthermore, a novel therapy named baroreceptor stimulation therapy has shown promising data in both experimental and clinical experiments to handle resistant arterial hypertension. Both approaches may be highly relevant in patients who are intolerant to medications.
  FULL TEXT PDF  

Keywords

Resistant arterial hypertension renal denervation baroreceptor stimulation therapy




  • Send manuscript
  • Instructions for authors
  • Recent
  • TOP 5
  • Management of high blood pressure in older-adults: aging, senescence and ageism
    2022, Vol.33, Núm. S3
  • A review of non-pharmacological and pharmacological therapies to treat high...
    2022, Vol.33, Núm. S3
  • Impact of alternative therapies in the treatment of resistant systemic arterial...
    2022, Vol.33, Núm. S3
  • The mexican health-care system and high blood pressure
    2022, Vol.33, Núm. S3
  • Preamble
    2022, Vol.33, Núm. S3
  • Effectiveness and safety of amphepramone in a slow release as part of the...
    2007, Vol.18, Núm. 1
  • Official Mexican Standard NOM-030-SSA2-2009. For the prevention, detection,...
    2011, Vol.22, Núm. 3
  • Etiology and pathophysiology of type 2 diabetes mellitus
    2011, Vol.22, Núm. 1
  • Early repolarization. Normal or dangerous?
    2011, Vol.22, Núm. 3
  • Long QT syndrome secondary to drug interaction between hydroxychloroquine and...
    2018, Vol.29, Núm. 2


Cardiovascular and Metabolic Science Vol. 33, Num. S3, Julio-Septiembre 2022. Es una publicación trimestral editada por la Asociación Nacional de Cardiólogos de México. Magdalena 135. Col. Del Valle. Del. Benito Juárez. Ciudad de México, México. C.P. 03103. Tel. 5556368002 https://www.cardiovascularandmetabolicscience.org.mx/ ancam@ancam.org.mx Editor responsable. Dr. Eduardo Meaney Mendiolea. Reserva de Derechos al Uso Exclusivo Nº 04-2019-061316491900-203. ISSN: EN TRÁMITE. Ambos otorgados por el Instituto Nacional del Derecho de Autor. Responsable de la última actualización de este número, Departamento de Internet, Graphimedic, S.A. de C.V., Ing. Luis Rosales Jiménez, Coquimbo 936, Col. Lindavista, Delegación Gustavo A. Madero, C.P. 07300, Ciudad de México, México. Fecha de última modificación, 4 de abril de 2022.

 

2022     |     https://www.cardiovascularandmetabolicscience.org.mx/